SCHEMBL16416319

SCHEMBL16416319

CCc1nc(C)nn1CC(=O)O

nearest known ligand 0.46

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 2/20 0.46
LMNA P02545 1/20 0.44
GAA P10253 1/20 0.43
SMN1; SMN2 Q16637 1/20 0.42
ALOX15 P16050 1/20 0.41
L3MBTL1 Q9Y468 2/20 0.38
TP53 P04637 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
KDM4E B2RXH2 2/20 0.34
NPSR1 Q6W5P4 1/20 0.34
TDP1 Q9NUW8 1/20 0.34
RAB9A P51151 1/20 0.34
CYP19A1 P11511 1/20 0.33
CXCR3 P49682 1/20 0.33
KCNH2 Q12809 1/20 0.33
MEN1 O00255 1/20 0.33
KMT2A Q03164 1/20 0.33
POLB P06746 1/20 0.33
MAPT P10636 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3588529 0.79 ALDH1A1 (0.50) ALDH1A1LMNAGAASMN1; SMN2ALOX15
Hydrochloric Acid SCHEMBL1374124 0.77 ALDH1A1 (0.48) ALDH1A1LMNAGAASMN1; SMN2ALOX15
SCHEMBL21960147 0.76 ADORA2A (0.33)
SCHEMBL16415983 0.70 LMNA (0.49) ALDH1A1LMNAGAASMN1; SMN2ALOX15
SCHEMBL20223332 0.68 KDM4C (0.54) ALDH1A1LMNAGAASMN1; SMN2ALOX15
SCHEMBL9342106 0.67
SCHEMBL17927903 0.67 LMNA (0.41) ALDH1A1LMNAGAASMN1; SMN2ALOX15
SCHEMBL19007302 0.67 ALDH1A1 (0.65) ALDH1A1LMNAGAAALOX15PTGDR2
SCHEMBL13031308 0.66 CYP19A1 (0.58) ALDH1A1LMNASMN1; SMN2ALOX15KDM4E
SCHEMBL7121270 0.64 LMNA (0.42) ALDH1A1LMNAGAAALOX15MAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107250133-B Hydroxyalkyl piperazine derivatives as CXCR3 receptor modulators 爱杜西亚药品有限公司 2020-09-15 CN disclosed
US-10259807-B2 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives IDORSIA PHARMACEUTICALS LTD. (SE) 2019-04-16 US disclosed
CN-105658649-B 1- (piperazine -1- base) -2- ([1,2,4] triazol-1-yl)-ethanone derivatives 爱杜西亚药品有限公司 2019-03-22 CN disclosed
EP-3245203-B1 HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS IDORSIA PHARMACEUTICALS LTD (CH) 2018-11-14 EP disclosed
US-10053457-B2 Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators IDORSIA PHARMACEUTICALS LTD. (CH) 2018-08-21 US disclosed
EP-3024832-B1 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2018-03-28 EP disclosed
US-20180009799-A1 HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2018-01-11 US disclosed
EP-3245203-A1 HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS Idorsia Pharmaceuticals Ltd (CH) 2017-11-22 EP disclosed
CN-107250133-A Hydroxyalkyl piperazine derivatives as CXCR3 receptor modulators 爱杜西亚药品有限公司 2017-10-13 CN disclosed
WO-2016113344-A1 HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS ACTELION PHARMACEUTICALS LTD (CH) 2016-07-21 WO disclosed
US-20160176862-A1 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES IDORSIA PHARMACEUTICALS LTD (CH) 2016-06-23 US disclosed
CN-105658649-A 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives 埃科特莱茵药品有限公司 2016-06-08 CN disclosed
EP-3024832-A1 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES Actelion Pharmaceuticals Ltd. (CH) 2016-06-01 EP disclosed
WO-2015011099-A1 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES ACTELION PHARMACEUTICALS LTD (CH) 2015-01-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10053457-B2 Hydroxyalkyl-piperazine derivatives as CXCR3 receptor modulators CXCR3, CXCR1, CXCR2 ALDH1A1 1096/4885LMNA 4610/4885GAA 4790/4885
US-20180009799-A1 HYDROXYALKYL-PIPERAZINE DERIVATIVES AS CXCR3 RECEPTOR MODULATORS CXCR3, CXCR1, CXCR2 ALDH1A1 1096/4885LMNA 4610/4885GAA 4790/4885
US-10259807-B2 1-(piperazin-1-yl)-2-([1,2,4]triazol-1-yl)-ethanone derivatives CXCR3, CXCR1, CXCR2 ALDH1A1 1093/4885LMNA 4374/4885GAA 4502/4885
US-20160176862-A1 1-(PIPERAZIN-1-YL)-2-([1,2,4]TRIAZOL-1-YL)-ETHANONE DERIVATIVES CXCR3, CXCR1, CXCR2 ALDH1A1 1093/4885LMNA 4374/4885GAA 4502/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.